ACADIA Pharmaceuticals to Webcast Its Analyst and Investor Meeting on December 14, 2007
SAN DIEGO–(BUSINESS WIRE)–Dec. 6, 2007–ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will host a live webcast of its Analyst and Investor Meeting to be held in New York City on Friday, December 14, 2007, from 8:00 a.m. to 10:30 a.m. Eastern Time.
The program will feature presentations by ACADIA management and leading clinicians and will include an overview of the therapeutic areas of schizophrenia and Parkinson’s disease psychosis as well as a presentation of data from ACADIA’s Phase II schizophrenia co-therapy trial with pimavanserin and a review of ACADIA’s Phase III program with pimavanserin for Parkinson’s disease psychosis, its Phase II program with ACP-104 for schizophrenia, and other discovery and development activities.
To access the webcast, please log onto ACADIA’s website at www.acadia-pharm.com and click on to the investors section approximately 10 minutes prior to the start of the webcast to allow for any software downloads that may be necessary. An archived recording of the event will be available on ACADIA’s website through December 28, 2007.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five mid-to-late stage clinical programs as well as a portfolio of preclinical and discovery assets directed at diseases with large unmet medical needs, including schizophrenia, Parkinson’s disease psychosis, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA’s product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA’s corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc. Lisa Barthelemy, Director, Investor Relations Thomas H. Aasen, Vice President and Chief Financial Officer 858-558-2871 SOURCE: ACADIA Pharmaceuticals Inc.